UA130338C2 - Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування - Google Patents
Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосуванняInfo
- Publication number
- UA130338C2 UA130338C2 UAA202102037A UAA202102037A UA130338C2 UA 130338 C2 UA130338 C2 UA 130338C2 UA A202102037 A UAA202102037 A UA A202102037A UA A202102037 A UAA202102037 A UA A202102037A UA 130338 C2 UA130338 C2 UA 130338C2
- Authority
- UA
- Ukraine
- Prior art keywords
- group
- antibodies
- ligand
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811123833 | 2018-09-26 | ||
| PCT/CN2019/107873 WO2020063676A1 (zh) | 2018-09-26 | 2019-09-25 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130338C2 true UA130338C2 (uk) | 2026-01-28 |
Family
ID=69953349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202102037A UA130338C2 (uk) | 2018-09-26 | 2019-09-25 | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12617867B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3858386A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7558156B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102989942B1 (cg-RX-API-DMAC7.html) |
| CN (4) | CN112512591B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019349207B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021004656A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3114137A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021003382A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI826543B (cg-RX-API-DMAC7.html) |
| UA (1) | UA130338C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020063676A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202102544B (cg-RX-API-DMAC7.html) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7408646B2 (ja) * | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途 |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| AU2020288275A1 (en) * | 2019-06-06 | 2022-02-03 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Anti-B7-H4 antibody–drug conjugate and medicinal use thereof |
| AU2020402006A1 (en) * | 2019-12-12 | 2022-07-07 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| JP7821733B2 (ja) | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| CN114845740B (zh) | 2020-01-31 | 2026-06-02 | 先天制药公司 | 癌症的治疗 |
| CA3175048A1 (en) * | 2020-03-25 | 2021-09-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for antibody medicament conjugate |
| CN115103691B (zh) | 2020-03-25 | 2025-01-24 | 苏州盛迪亚生物医药有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
| MX2022011808A (es) * | 2020-03-25 | 2022-12-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo. |
| BR112022024930A2 (pt) | 2020-06-08 | 2022-12-27 | Baili Bio Chengdu Pharmaceutical Co Ltd | Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo |
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| EP4190812A4 (en) | 2020-07-27 | 2024-09-04 | Tuojie Biotech (Shanghai) Co., Ltd. | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS PHARMACEUTICAL USE |
| EP4768463A2 (en) * | 2020-08-13 | 2026-07-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibody drug conjugate |
| NZ781239A (en) * | 2020-09-15 | 2024-11-29 | Systimmune Inc | A camptothecin drug and its antibody conjugate thereof |
| CN114249798A (zh) * | 2020-09-24 | 2022-03-29 | 江苏恒瑞医药股份有限公司 | 一种依喜替康类似物的结晶形式及其制备方法 |
| DK4516357T3 (da) * | 2020-09-30 | 2026-04-27 | Duality Biologics Suzhou Co Ltd | Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
| AU2021354827A1 (en) | 2020-09-30 | 2023-06-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition |
| EP4227310A4 (en) * | 2020-10-12 | 2024-11-06 | Sichuan Baili Pharmaceutical Co. Ltd. | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF |
| WO2022078259A1 (zh) | 2020-10-12 | 2022-04-21 | 四川百利药业有限责任公司 | 一种氘代的喜树碱衍生物及其抗体药物偶联物 |
| CN116133694B (zh) * | 2020-10-14 | 2026-03-06 | 苏州盛迪亚生物医药有限公司 | 抗her3抗体和抗her3抗体药物偶联物及其医药用途 |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| AU2021394411A1 (en) * | 2020-12-11 | 2023-07-06 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Novel camptothecin derivative, composition containing same, and use thereof |
| CN114652853B (zh) * | 2020-12-22 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体-药物偶联物及医药用途 |
| JP2024504454A (ja) * | 2021-01-29 | 2024-01-31 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 抗体-薬物コンジュゲート及びその医学的使用 |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| WO2022171115A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
| WO2022194257A1 (zh) * | 2021-03-17 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
| WO2023178641A1 (zh) | 2022-03-25 | 2023-09-28 | 成都百利多特生物药业有限责任公司 | 一种dna毒性二聚体化合物及其偶联物 |
| CN115197088A (zh) * | 2021-04-02 | 2022-10-18 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物中间体的制备方法 |
| CN115197234B (zh) * | 2021-04-02 | 2026-06-12 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物中间体的制备方法 |
| TW202302595A (zh) * | 2021-04-15 | 2023-01-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 依喜替康類似物的結晶形式及其製備方法 |
| TW202302649A (zh) | 2021-04-26 | 2023-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗nectin-4抗體和抗nectin-4抗體-藥物偶聯物及其醫藥用途 |
| CN113816969B (zh) * | 2021-04-30 | 2024-01-16 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| AU2022269073A1 (en) * | 2021-05-07 | 2023-11-23 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| CN115385926B (zh) * | 2021-05-24 | 2025-06-03 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| CN115557962A (zh) * | 2021-07-02 | 2023-01-03 | 石药集团巨石生物制药有限公司 | 新型喜树碱类化合物及其制备方法和应用 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| CA3225598A1 (en) | 2021-07-21 | 2023-01-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing anti-trop2 antibody drug conjugate and its application |
| CN115850291B (zh) * | 2021-09-24 | 2024-11-15 | 石药集团巨石生物制药有限公司 | 喜树碱衍生物及其用途 |
| EP4410307A4 (en) | 2021-09-30 | 2026-05-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PYRROLO BENZODIAZEPINE DERIVATIVE AND CONJUGATE, PROCESS FOR THEIR PREPARATION AND USE |
| CN118201613A (zh) * | 2021-10-14 | 2024-06-14 | 江苏恒瑞医药股份有限公司 | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン,インコーポレイテッド | 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用 |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| KR20240142405A (ko) | 2021-11-17 | 2024-09-30 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 항체-약물 복합체 및 그의 용도 |
| CN116212044A (zh) | 2021-12-03 | 2023-06-06 | 成都百利多特生物药业有限责任公司 | 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途 |
| CN118414339A (zh) * | 2021-12-16 | 2024-07-30 | 迈威(上海)生物科技股份有限公司 | 一种喜树碱类化合物及其偶联物 |
| CN118302448A (zh) | 2021-12-28 | 2024-07-05 | 江苏恒瑞医药股份有限公司 | 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途 |
| CA3248952A1 (en) | 2022-01-26 | 2025-07-10 | Shanghai Mabgen Biotech Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD79B ANTIBODY-DRUG CONJUGATE AND ITS USE |
| EP4470570A1 (en) * | 2022-01-28 | 2024-12-04 | Duality Biologics (Suzhou) Co., Ltd. | Her3 antibody-drug conjugate and use thereof |
| US20250195681A1 (en) * | 2022-03-18 | 2025-06-19 | Duality Biologics (Suzhou) Co., Ltd. | Anti-gpc3 antibody drug conjugate and use thereof |
| CA3248038A1 (en) * | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES |
| EP4514350A1 (en) * | 2022-04-29 | 2025-03-05 | Shanghai MicuRx Pharmaceutical Co., Ltd. | Ligand-drug conjugate of camptothecin analogs, intermediates, preparation method therefor, pharmaceutical composition and application thereof |
| CN116966314A (zh) | 2022-04-29 | 2023-10-31 | 成都百利多特生物药业有限责任公司 | 一种包含亲水性糖结构的配体-药物偶联物 |
| WO2023217227A1 (zh) | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| AU2023273063A1 (en) | 2022-05-16 | 2024-11-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing anti-nectin-4 antibody drug conjugate and use thereof |
| IL317037A (en) | 2022-05-18 | 2025-01-01 | Systimmune Inc | Ligand-drug conjugate and its uses |
| AU2023282410A1 (en) * | 2022-06-07 | 2024-12-05 | Duality Biologics (Suzhou) Co., Ltd. | Anti-b7h3 antibody-drug conjugate and use thereof |
| JP2025519421A (ja) * | 2022-06-09 | 2025-06-26 | ベイジーン スイッツァランド ゲーエムベーハー | 抗体薬物複合体 |
| CN118955614B (zh) * | 2022-07-05 | 2025-12-30 | 上海药明合联生物技术有限公司 | 偶联连接子 |
| WO2024012566A2 (en) | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| CN117024438B (zh) * | 2022-07-29 | 2026-05-05 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
| CN120225528A (zh) * | 2022-09-02 | 2025-06-27 | 默沙东有限责任公司 | 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途 |
| CN117752813A (zh) | 2022-09-26 | 2024-03-26 | 成都百利多特生物药业有限责任公司 | 抗cd33抗体和抗cd33抗体-药物偶联物及其用途 |
| AU2023349279A1 (en) * | 2022-09-30 | 2025-05-15 | Beone Medicines I Gmbh | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| KR20250079227A (ko) | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| KR20250106301A (ko) | 2022-11-28 | 2025-07-09 | 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 | 항-her3 항체-약물 접합체 조성물 및 이의 의약적 용도 |
| WO2024131835A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
| EP4653020A1 (en) | 2023-01-19 | 2025-11-26 | Shanghai Shengdi Pharmaceutical Co., Ltd | Tyrosinase-mediated protein site-specific conjugation and use thereof |
| PE20252164A1 (es) | 2023-01-19 | 2025-09-04 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Conjugado de anticuerpo-farmaco anti-her2 para el tratamiento del cancer de mama |
| IL322887A (en) | 2023-02-27 | 2025-10-01 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Anti-DLL3 antibody, antibody-drug conjugate and pharmaceutical use thereof |
| KR20250152646A (ko) | 2023-03-01 | 2025-10-23 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 인데노[1,2-b]퀴놀린-10,13-디온 유도체의 제조 방법 |
| TW202438069A (zh) * | 2023-03-30 | 2024-10-01 | 大陸商上海齊魯製藥研究中心有限公司 | 依喜替康衍生物及其抗體藥物偶聯物 |
| KR20250174033A (ko) * | 2023-04-23 | 2025-12-11 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 항체 약물 접합체의 이용 |
| AU2024261955A1 (en) | 2023-04-28 | 2025-10-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-tf antibody and anti-tf antibody-drug conjugate and medical use thereof |
| WO2024227432A1 (zh) * | 2023-04-30 | 2024-11-07 | 泰诚思(上海)生物医药有限公司 | 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用 |
| TW202448950A (zh) | 2023-05-08 | 2024-12-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種抗體或其抗原結合片段、抗體-藥物偶聯物及其應用 |
| WO2024230752A1 (zh) * | 2023-05-08 | 2024-11-14 | 甘李药业股份有限公司 | 喜树碱衍生物、接头、配体-药物偶联物及其医药用途 |
| KR20260011720A (ko) * | 2023-05-16 | 2026-01-23 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 항체-약물 접합체를 포함하는 약제 조성물 |
| CN121443617A (zh) * | 2023-05-31 | 2026-01-30 | 甘李药业股份有限公司 | 依喜替康衍生物、及其配体-药物偶联物、抗体偶联物及用途 |
| JPWO2024248123A1 (cg-RX-API-DMAC7.html) | 2023-06-02 | 2024-12-05 | ||
| WO2025031285A1 (zh) | 2023-08-04 | 2025-02-13 | 江苏恒瑞医药股份有限公司 | 抗psma抗体-药物偶联物及其医药用途 |
| CN120958033B (zh) * | 2023-08-04 | 2026-03-31 | 映恩生物制药(苏州)有限公司 | 抗体药物偶联物的识别抗体及其应用 |
| TW202513096A (zh) | 2023-09-22 | 2025-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗her3抗體藥物偶聯物治療腫瘤的用途和方法 |
| IL324001A (en) * | 2023-09-22 | 2025-12-01 | Obi Pharma Inc | Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof |
| CN122161619A (zh) * | 2023-10-25 | 2026-06-05 | 正大天晴药业集团南京顺欣制药有限公司 | 抗her2抗体药物偶联物治疗乳腺癌的用途 |
| WO2025087358A1 (zh) * | 2023-10-27 | 2025-05-01 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物用于治疗癌症的方法 |
| EP4548971A1 (en) | 2023-11-06 | 2025-05-07 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | 1,4-benzothiazepines and related compounds with cyclopropanol groups as multi-targeted drugs |
| TW202540115A (zh) | 2023-11-16 | 2025-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | 一種氘代喜樹鹼化合物及其製備和應用 |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| KR20260117777A (ko) | 2023-11-24 | 2026-07-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항-her3 항체-약물 접합체 및 항-vegf 항체에 의한 종양의 치료 방법 |
| CN122374343A (zh) | 2023-11-30 | 2026-07-10 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| AU2024415931A1 (en) | 2023-12-27 | 2026-07-16 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Multi-specific antibody targeting her3 and trop2 and conjugate thereof |
| WO2025156953A1 (zh) * | 2024-01-23 | 2025-07-31 | 上海池汐生物医药科技有限公司 | 一种多肽偶联物及其应用 |
| WO2025176180A1 (zh) * | 2024-02-23 | 2025-08-28 | 江苏恒瑞医药股份有限公司 | 艾日布林衍生物药物偶联物用于治疗肿瘤的用途 |
| WO2025199665A1 (en) * | 2024-03-23 | 2025-10-02 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| TW202602944A (zh) * | 2024-04-03 | 2026-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗cldn6抗體、其抗體-藥物偶聯物及其醫藥用途 |
| WO2025228377A1 (zh) * | 2024-04-29 | 2025-11-06 | 上海甫弘生物医药有限公司 | B7-h3/egfr结合分子及其医药用途 |
| WO2025242097A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技(成都)有限公司 | 喜树碱类化合物及其偶联物和用途 |
| WO2025252039A1 (zh) * | 2024-06-03 | 2025-12-11 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物治疗非小细胞肺癌的用途 |
| TW202613132A (zh) * | 2024-06-06 | 2026-04-01 | 大陸商海思科醫藥集團股份有限公司 | 喜樹鹼類衍生物及其用途 |
| WO2026046410A1 (zh) * | 2024-09-02 | 2026-03-05 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物与免疫检查点抑制剂的组合 |
| WO2026082091A1 (zh) * | 2024-10-16 | 2026-04-23 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合egfr和muc1的抗体药物偶联物的药物组合物 |
| WO2026130368A1 (zh) * | 2024-12-19 | 2026-06-25 | 映恩生物制药(苏州)有限公司 | 一种药物偶联物中间体及其制备方法 |
| WO2026138778A1 (zh) * | 2024-12-23 | 2026-07-02 | 江苏恒瑞医药股份有限公司 | 一种包含抗c-Met抗体-药物偶联物的药物组合物及其用途 |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2026158702A1 (zh) * | 2025-01-27 | 2026-07-30 | 上海睿智医药研究集团有限公司 | 一种抗肿瘤药物、药物组合物及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂 |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| WO2008025020A2 (en) | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
| ZA200902161B (en) | 2006-10-27 | 2010-06-30 | Genentech Inc | Antiobodies and immunoconjugates and uses therefor |
| JP2015506349A (ja) | 2011-12-21 | 2015-03-02 | アルデリックス, インコーポレイテッド | 非全身性tgr5アゴニスト |
| CN104168899B (zh) | 2012-01-13 | 2017-04-05 | 通用医疗公司 | 麻醉剂化合物及其相关的使用方法 |
| ES2690315T3 (es) | 2012-06-15 | 2018-11-20 | Mitsubishi Tanabe Pharma Corporation | Compuestos de imidazol y triazol como inhibidores de DGAT-1 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
| CN111150851A (zh) | 2015-02-15 | 2020-05-15 | 江苏恒瑞医药股份有限公司 | 配体-细胞毒性药物偶联物、其制备方法及其应用 |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| WO2019034177A1 (zh) | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| JP7408646B2 (ja) * | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途 |
| AU2020288275A1 (en) * | 2019-06-06 | 2022-02-03 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Anti-B7-H4 antibody–drug conjugate and medicinal use thereof |
-
2019
- 2019-09-25 UA UAA202102037A patent/UA130338C2/uk unknown
- 2019-09-25 BR BR112021004656-9A patent/BR112021004656A2/pt unknown
- 2019-09-25 US US17/280,129 patent/US12617867B2/en active Active
- 2019-09-25 CN CN201980049841.2A patent/CN112512591B/zh active Active
- 2019-09-25 KR KR1020217010625A patent/KR102989942B1/ko active Active
- 2019-09-25 AU AU2019349207A patent/AU2019349207B2/en active Active
- 2019-09-25 WO PCT/CN2019/107873 patent/WO2020063676A1/zh not_active Ceased
- 2019-09-25 CN CN202411019975.9A patent/CN118806924A/zh active Pending
- 2019-09-25 CN CN202411019712.8A patent/CN118903456A/zh active Pending
- 2019-09-25 KR KR1020267021221A patent/KR20260118519A/ko active Pending
- 2019-09-25 CA CA3114137A patent/CA3114137A1/en active Pending
- 2019-09-25 MX MX2021003382A patent/MX2021003382A/es unknown
- 2019-09-25 EP EP19866595.2A patent/EP3858386A4/en active Pending
- 2019-09-25 CN CN202411020354.2A patent/CN119185572A/zh active Pending
- 2019-09-25 JP JP2021516798A patent/JP7558156B2/ja active Active
- 2019-09-26 TW TW108135663A patent/TWI826543B/zh active
-
2021
- 2021-04-16 ZA ZA2021/02544A patent/ZA202102544B/en unknown
-
2026
- 2026-03-02 US US19/554,518 patent/US20260201063A1/en active Pending
- 2026-03-02 US US19/554,510 patent/US20260201062A1/en active Pending
- 2026-04-08 AU AU2026202631A patent/AU2026202631A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260201062A1 (en) | 2026-07-16 |
| KR20260118519A (ko) | 2026-07-30 |
| CN118903456A (zh) | 2024-11-08 |
| CN112512591B (zh) | 2024-08-16 |
| EP3858386A1 (en) | 2021-08-04 |
| US20210353764A1 (en) | 2021-11-18 |
| AU2019349207A1 (en) | 2021-04-08 |
| AU2026202631A1 (en) | 2026-04-30 |
| TW202027795A (zh) | 2020-08-01 |
| EP3858386A4 (en) | 2022-10-12 |
| BR112021004656A2 (pt) | 2021-06-01 |
| CN119185572A (zh) | 2024-12-27 |
| WO2020063676A1 (zh) | 2020-04-02 |
| AU2019349207B2 (en) | 2026-01-08 |
| US20260201063A1 (en) | 2026-07-16 |
| JP7558156B2 (ja) | 2024-09-30 |
| KR20210066833A (ko) | 2021-06-07 |
| CN118806924A (zh) | 2024-10-22 |
| KR102989942B1 (ko) | 2026-07-09 |
| JP2022511351A (ja) | 2022-01-31 |
| US12617867B2 (en) | 2026-05-05 |
| ZA202102544B (en) | 2023-10-25 |
| MX2021003382A (es) | 2021-05-27 |
| TWI826543B (zh) | 2023-12-21 |
| CA3114137A1 (en) | 2020-04-02 |
| CN112512591A (zh) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102544B (en) | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CL2021000387A1 (es) | Compuestos de anillo fusionado | |
| SA520420033B1 (ar) | مركبات صيدلية | |
| CY1122566T1 (el) | Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| GEAP202515818A (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| JOP20210259A1 (ar) | مستقبل استروجين يحلل خمير يستهدف التحلل البروتيني | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| CR20220126A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| MX2021011081A (es) | Derivados de nicorandil. | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| WO2019224790A3 (en) | Prodrugs of fulvestrant | |
| WO2019054891A3 (en) | Trpv2 antagonists | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| MX373162B (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
| JOP20200079A1 (ar) | مثبطات مستقبل عامل نمو البشرة |